Report Description Table of Contents Industry Report and Statistics (Facts & Figures) - Sales Volume, ASP & Number of Procedure Conducted by Product Type, Devices & Application The global injectable drug delivery market will witness a robust CAGR of 11.78%, valued at $615.87 billion in 2021, expected to appreciate and reach $1677.91 billion by 2030, confirms Strategic Market Research. Key Industry Drivers - Increase in the Number of Chronic Diseases, Needle Injuries, and Usage of Injections Worldwide The continuous rising prevalence of chronic diseases across the globe is one of the primary factors driving the overall growth of this market. According to National Health Council, chronic diseases affect nearly 133 Mn people in the United States, representing approximately more than 40% of the country's total population. By 2020, that number will rise to an estimated 157 Mn, out of which 81 Mn people have multiple conditions. As per WHO, Chronic/Non-communicable diseases (NCDs) kill about 41 Mn people each year, which is equivalent to approximately 71% of all deaths worldwide. More than 15 Mn people die each year due to NCD between (30 to 69) years of age, whereas 85% of these "premature" deaths occur in lower- and middle-income countries. CVDs (cardiovascular diseases) account for the highest number of NCD deaths (17.9 million people each year), followed by cancers (9.3 Mn), respiratory diseases (4.1 Mn), and Diabetes (1.5 Mn). Apart from the rise of chronic diseases worldwide, the rapid technological advancements of injectables, the increasing use of biologics, the growing occurrence of needlestick injuries, etc., are propelling the market growth worldwide. As per the CDC (Centers for Disease Control & Prevention), the health care workers in the United States suffer between 600,000 to 1 Mn needle sticks and other sharp injuries each year. Furthermore, the continuous rise in demand for in situ forming implants, drug implants, Polymer-based microspheres, Oil-based injectable solutions, injectable drug suspensions, and Sustained-Release Injectable Drug Delivery are fuelling the market growth extensively across the world. Restraints - Risk of Blood-Borne Diseases and Product Recalls Needle sharing or sharing syringes have a higher risk of transmitting blood-borne diseases among the users, such as Hepatitis C and HIV-AIDS. Abscessed infections of injection sites occur due to the lack of proper hygiene and aseptic technique during the injection process. These factors are highly restraining the overall market growth. If a product is recalled, the entire process of retrieving and replacing the defective product can cause a company to incur a huge number of losses associated with the replacement and fixing of faulty products. Due to these huge losses, the company's revenue and share in the injectable drug delivery devices market will get hampered, which in turn will highly obstruct the overall market growth. Opportunities - Increase of Government Funds on Contraceptive Injectables Raising funds by the governments worldwide on contraceptive injectables like DMPA (Depot Medroxy Progesterone Acetate) and Norethisterone enanthate (NET-EN) is expected to create ample growth opportunities in the future, thereby accelerating the overall market growth. Market Analysis Of Different Segments Covered in the Report Based on Device Type Convention Injectables Pre-filled syringes Auto-Injectors Pen-Injectables Wearable Based on Products Freeze Dried Products Injectable Sterile Products Based on Applications Hormonal Disorders Auto-Immune Diseases Oncology Orphan/Rare Diseases Others Based on End-User Hospitals Home Care Settings Others Regional Coverage Analysis North America United States Mexico Canada Rest of North America Europe Switzerland Russia France Germany U.K Finland Turkey Netherlands Belgium Spain Italy Rest of Europe Asia Pacific China India Indonesia South Korea Thailand Japan Singapore Malaysia Philippines Australia New Zealand Rest of APAC LAMEA Brazil Saudi Arabia Uruguay Argentina Rest of LAMEA Segments Analysis & Insights Based on Device Type, the 'Convention Injectables' dominated the market significantly in 2020 with a steady CAGR. The continuous increase in the number of infectious diseases worldwide, higher sales of traditional syringes due to an increase in hospital admissions, rise in the number of surgeries performed, and several immunization programs worldwide are driving the growth of this segment. Based on Product, the 'Injectable Sterile Products' held the highest share of nearly 67.38% of the entire market in 2020 due to its high storage capacity and quality assurance. These products are highly preferred by surgeons in hospitals for treating complex diseases. These injectable sterile are pathogen-free and thus less prone to infection risk. All of these pivotal factors are propelling the overall growth of this segment. Based on Applications, the' Hormonal Disorders' segment dominated the injectable drug delivery market in 2020 with a steady CAGR. Factors like Eating disorders, thyroid problems, stress issues, low sex drive, irregular periods, unexplained weight gain, and mood swings augment the overall segment growth. Based on End-User, the 'Hospitals' segment significantly dominated with the highest share, almost 62.17% of the total market. The rise of funding by the worldwide governments for healthcare sectors and the longer duration of the patient's stay in hospitals suffering from chronic or acute diseases are accelerating the overall growth of this segment. Based on Regions, North America significantly dominated the injectable drug delivery devices market with the highest share in 2020 (almost 194.89 billion) and a CAGR of 12.87%. The higher adoption rate of drug delivery technologies for Diabetes, cancer, and other autoimmune disorders propels the overall market growth in this region. As per ADA (American Diabetes Association), in 2018, nearly 30.3 Mn people in the United States were diagnosed with Diabetes. The Asia-Pacific region held the fastest growth rate in 2020 with a robust CAGR owing to the rising patient pool, increase in growth of healthcare sectors, and a shift from conventional drug delivery injectables to readily used injectables. Global Injectable Drug Delivery Market Competitive Landscape Analysis A 360-degree competitive landscape is crucial in figuring out the main competitors that are prevailing in the global market environment. The comparison is performed based on the total revenue generated, company strengths and flaws, company overview, global presence, market initiatives, market potential, company financials, investments in the field of R&D, production capability, production sites & facilities, etc. Becton, Dickinson, and Company Pfizer Inc. Teva Pharmaceuticals Industries Ltd. Eli Lilly and Company Baxter International, Inc. Schott AG Gerresheimer Ypsomed B. Braun Melsungen Injectable Drug Delivery Market Report Coverage Report Attribute Details Forecast Period 2021 - 2030 The market size value in 2021 USD 615.87 Billion The revenue forecast in 2030 USD 1677.91 Billion Growth rate CAGR of approximately 11.78% The base year for estimation 2021 Historical data 2017 – 2020 Unit USD Billion, CAGR (2021 - 2030) Segmentation By Device Type, By Products, By Applications, By End-User, By Region. By Device Type Convention Injectables, Pre-filled syringes, Auto-Injectors, Pen-Injectables, Wearable By Products Freeze Dried Products, Injectable Sterile Products. By Applications Hormonal Disorders, Auto-Immune Diseases, Oncology, Orphan/Rare Diseases, Others. By End-User Hospitals, Home Care Settings, Others. By Region North America, Europe, Asia Pacific, Rest of Asia-Pacific. Country Scope United States of America, United Kingdom, Italy, Germany, France, Spain, Canada, China, India, Japan, Brazil, Argentina, Mexico, South Africa, Saudi Arabia, etc. Company Usability Profiles Becton, Dickinson, and Company, Pfizer Inc., Teva Pharmaceuticals Industries Ltd, Eli Lilly and Company, Baxter International, Inc, Schott AG, Gerresheimer, Ypsomed. B. Braun Melsungen. Recent Developments On August 8th, 2022, a group of scientists from the UNC Medicine School of North Carolina, USA, developed a highly advanced Injectable Drug-Delivery System known as Rifabutin for treating Tuberculosis. It is generally for those people who can’t tolerate rifampin, like people suffering from AIDS/HIV. In the case of active tuberculosis, it is most commonly used with other sorts of antimycobacterial medications. On Dec 2nd, 2020, Becton, Dickinson, and Company announced that it has planned to invest a total amount of nearly US$1.2 Bn in the Pre-Fillable Syringe Manufacturing Capacity over the upcoming 4 years for the expansion and up-gradation of manufacturing capacity & technology for the pre-fillable syringes (PFS) & advanced drug delivery systems (ADDS) across the 6 global manufacturing locations & add a new manufacturing facility in the European Union. On Oct 5th, 2020, SCHOTT AG & Credence MedSystems formed a Strategic Collaboration Agreement to make Syringe Injections safer for the benefit of patients worldwide. Credence MedSystems, one of the leading innovators of injectable drug delivery technologies, developed the Companion Safety Syringe System. This companion would allow the pharmaceutical manufacturers to provide critical usability & safety features to their end-users while integrating with the existing syringe barrels and the primary packaging components. Frequently Asked Question About This Report Which geographical region held the maximum share of the market? Based on Regions, North America significantly dominated the market with the highest share in 2020 (almost 194.89 billion) and a CAGR of 12.87%. What are the vital factors driving the overall growth of the market? Some of the crucial factors that are augmenting the overall growth of the market are the continuous increase in the number of chronic diseases needle injuries, & the more and more usage of injections worldwide. Which Product segment has the largest share of the market? Based on Product, the Injectable Sterile Products held the highest share of nearly 67.38% of the entire market in 2021. Who are the crucial players prevailing in the market? The leading industry players of the market are Becton, Dickinson, and Company, Teva Pharmaceuticals Industries Ltd, Pfizer Inc, Eli Lilly and Company, Schott AG, Gerresheimer, Ypsomed, Baxter International Inc, and B. Braun Melsungen. How big is this injectable drug delivery Market size ? The global injectable drug delivery market size was $615.87 Bn in 2021 and is predicted to reach $1677.91 Bn by 2030, representing a CAGR of 11.78%. What is the injectable drug delivery market growth? The global injectable drug delivery market is expected to grow at a compound annual growth rate (CAGR) of 11.78% from 2021 to 2030 to reach USD 1677.91 Billion by 2030. Sources https://nationalhealthcouncil.org/wp-content/uploads/2019/12/NHC_Files/Pdf_Files/AboutChronicDisease.pdf https://www.who.int/data/gho/data/themes/topics/topic-details/GHO/ncd-mortality https://diabetes.org/about-us/statistics/about-diabetes https://news.unchealthcare.org/2022/08/scientists-create-long-acting-injectable-drug-delivery-system-for-tuberculosis/ 1. Introduction 1.1. Study Objective 1.2. Market Definition 1.3. Study Scope 1.3.1. Markets Covered 1.3.2. Geographic Scope 1.3.3. Years Considered 1.3.4. Stakeholders 2. Research Methodology 2.1. Data Procurement 2.2. Paid Database 2.2.1. Secondary Data 2.2.1.1. Key Secondary sources 2.2.2. Primary Data 2.2.2.1 Primary sources 2.2.2.2. Key industry insights 2.2.2.3. Primary interviews with experts 2.2.2.4. Key primary respondent list 2.3. Market Size Estimation 2.4. Bottom-Up and Top-Down Approaches 2.4.1. Bottom-Up Approach 2.4.1.1. Approach for arriving at market size by bottom-up analysis 2.4.2. Top-Down Approach 2.4.2.1. Approach for Capturing Market Size by Top-Down Analysis 2.5. Market Breakdown and Data Triangulation 2.6. Research Methodology 2.7. Risk Assessment 3. Executive Summary 3.1 Market: Post-Covid-19 3.1.1 Actual Scenario 3.1.2 Pessimistic Scenario 3.1.3 Optimistic Scenario 3.1.4 Market Summary 4. Industry Outlook 4.1 Market Snapshot 4.2 Global Injectable Drug Delivery Market 4.2.1 Global Market, 2021 – 2030 (USD Million) 4.3 Regional Business Analysis 4.3.1 Global Market, by region, 2021 - 2030 (USD Million) 4.4 By Product Business Analysis 4.4.1 Global Market, By Product, 2021 - 2030 (USD Million) 4.5 By Device Type Business Analysis 4.5.1 Global Market, By Device Type, 2021 - 2030 (USD Million) 4.6 Application Business Analysis 4.6.1 Global Market, By Application, 2021 - 2030 (USD Million) 4.6 End-User Business Analysis 4.6.1 Global Market, By End-User, 2021 - 2030 (USD Million) 4.7 Value Chain Analysis 4.8 Market Variable Analysis 4.8.1 Market Drivers Analysis 4.8.2 Market Restraints Analysis 4.9 Business Environment Analysis Tool 4.9.1 Market PEST analysis 4.9.2 Market Porter’s analysis 4.10 Penetration & Growth Prospect Mapping 5. Market Dynamics 5.1. Introduction 5.2. Market Dynamics 5.2.1. Drivers 5.2.2. Restraints 5.2.3. Opportunities 5.2.4. Challenges 5.3. Impact of Covid-19 On Market 5.4. Value Chain Analysis 5.5. Ecosystem 5.6. Patent Analysis 5.7. Trade Analysis 5.8. Tariff Analysis 5.9. Case Study Analysis 5.10. Porter’s Five Forces Analysis 5.10.1 Threat of New Entrants 5.10.2 Threat of Substitutes 5.10.3 Bargaining Power of Buyers 5.10.4 Bargaining Power of Suppliers 5.10.5 Degree of Competition 5.11. End-User Analysis 5.11.1. Trends in End-User (2014-2020) 5.11.2. Trends in End-User (2021-2028) 5.12. Pricing Analysis 5.12.1. Average Price Trend Analysis (By region, By Countries) 6. Competitive & Vendor Landscape 6.1. Company Market Share Analysis 6.2. Manufacturers Injectable Drug Delivery Manufacturing Sites, Area Served, Product Product 6.3. Market Competitive Situation and Trends 6.4. Manufacturers Mergers & Acquisitions, Expansion Plans 7. Global Market: By Product Segment Analysis 7.1. Introduction 7.2. Sales Volume & Revenue Analysis (2021-2030) 7.3. Freeze Dried Products 7.3.1. Freeze Dried Products market, 2021 - 2030 (USD Million) 7.4. Injectable Sterile Products 7.4.1. Injectable Sterile Products market, 2021 - 2030 (USD Million) 8. Global Market: By Device Type Segment Analysis 8.1. Introduction 8.2. Sales Volume & Revenue Analysis (2021-2030) 8.3. Convention Injectables 8.3.1. Convention Injectables market, 2021 - 2030 (USD Million) 8.4. Pre-filled syringes 8.4.1. Pre-filled syringes market, 2021 - 2030 (USD Million) 8.5. Auto-Injectors 8.5.1. Auto-Injectors market, 2021 - 2030 (USD Million) 8.6. Pen-Injectables 8.6.1. Pen-Injectables market, 2021 - 2030 (USD Million) 8.7. Wearable 8.7.1. Wearable market, 2021 - 2030 (USD Million) 9. Global Market: By Application Segment Analysis 9.1. Introduction 9.2. Sales Volume & Revenue Analysis (2021-2030) 9.3. Hormonal Disorders 9.3.1. Hormonal Disorders market, 2021 - 2030 (USD Million) 9.4. Auto-Immune Diseases 9.4.1. Auto-Immune Diseases market, 2021 - 2030 (USD Million) 9.5. Oncology 9.5.1. Oncology market, 2021 - 2030 (USD Million) 9.6. Orphan/Rare Diseases 9.6.1. Orphan/Rare Diseases market, 2021 - 2030 (USD Million) 9.7. Others 9.7.1. Others market, 2021 - 2030 (USD Million) 10. Global Market: By End-User Segment Analysis 10.1. Introduction 10.2. Sales Volume & Revenue Analysis (2021-2030) 10.3. Hospitals 10.3.1. Hospitals market, 2021 - 2030 (USD Million) 10.4. Home Care Settings 10.4.1. Home Care Settings market, 2021 - 2030 (USD Million) 10.5. Others 10.5.1. Others market, 2021 - 2030 (USD Million) 11. Global Market: Regional Outlook 11.1 North America 11.1.1. North America Market, by By Product, 2021 - 2030 (USD Million) 11.1.2. North America Market, by By Device Type, 2021 - 2030 (USD Million) 11.1.3. North America Market, by End-User, 2021 - 2030 (USD Million) 11.1.4. North America Market, by Country, 2021 - 2030 (USD Million) 11.1.4.1. U.S. 11.1.4.1.1. U.S. Market, by By Product, 2021 - 2030 (USD Million) 11.1.4.1.2. U.S. Market, by By Device Type, 2021 - 2030 (USD Million) 11.1.4.1.3. U.S. Market, by End-User, 2021 - 2030 (USD Million) 11.1.4.2. Canada 11.1.4.2.1. Canada Market, by By Product, 2021 - 2030 (USD Million) 11.1.4.2.2. Canada Market, by By Device Type, 2021 - 2030 (USD Million) 11.1.4.2.3. Canada Market, by End-User, 2021 - 2030 (USD Million) 11.2. Europe 11.2.1. Europe Market, by By Product, 2021 - 2030 (USD Million) 11.2.2. Europe Market, by By Device Type, 2021 - 2030 (USD Million) 11.2.3. Europe Market, by End-User, 2021 - 2030 (USD Million) 11.2.4. Europe Market, by country, 2021 - 2030 (USD Million) 11.2.4.1 U.K. 11.2.4.1.1. U.K. Market, by By Product, 2021 - 2030 (USD Million) 11.2.4.1.2. U.K. Market, by By Device Type, 2021 - 2030 (USD Million) 11.2.4.1.3. U.K. Market, by End-User, 2021 - 2030 (USD Million) 11.2.4.2. Germany 11.2.4.2.1. Germany Market, by By Product, 2021 - 2030 (USD Million) 11.2.4.2.2. Germany Market, by By Device Type, 2021 - 2030 (USD Million) 11.2.4.2.3. Germany Market, by End-User, 2021 - 2030 (USD Million) 11.2.4.3. France 11.2.4.3.1. France Market, by By Product, 2021 - 2030 (USD Million) 11.2.4.3.2. France Market, by By Device Type, 2021 - 2030 (USD Million) 11.2.4.3.3. France Market, by End-User, 2021 - 2030 (USD Million) 11.2.4.4. Rest of Europe 11.2.4.4.1. Rest of Europe Market, by By Product, 2021 - 2030 (USD Million) 11.2.4.4.2. Rest of Europe Market, by By Device Type, 2021 - 2030 (USD Million) 11.2.4.4.3. Rest of Europe Market, by End-User, 2021 - 2030 (USD Million) 11.3. Asia Pacific 11.3.1. Asia Pacific Market, by By Product, 2021 - 2030 (USD Million) 11.3.2. Asia Pacific Market, by By Device Type, 2021 - 2030 (USD Million) 11.3.3. Asia Pacific Market, by End-User, 2021 - 2030 (USD Million) 11.3.4. Asia Pacific Market, by country, 2021 - 2030 (USD Million) 11.3.4.1. China 11.3.4.1.1. China Market, by By Product, 2021 - 2030 (USD Million) 11.3.4.1.2. China Market, by By Device Type, 2021 - 2030 (USD Million) 11.3.4.1.3. China Market, by End-User, 2021 - 2030 (USD Million) 11.3.4.2. India 11.3.4.2.1. India Market, by By Product, 2021 - 2030 (USD Million) 11.3.4.2.2. India Market, by By Device Type, 2021 - 2030 (USD Million) 11.3.4.2.3. India Market, by End-User, 2021 - 2030 (USD Million) 11.3.4.3. Japan 11.3.4.3.1. Japan Market, by By Product, 2021 - 2030 (USD Million) 11.3.4.3.2. Japan Market, by By Device Type, 2021 - 2030 (USD Million) 11.3.4.3.3. Japan Market, by End-User, 2021 - 2030 (USD Million) 11.3.4.4. South Korea 11.3.4.4.1. South Korea Market, by By Product, 2021 - 2030 (USD Million) 11.3.4.4.2. South Korea Market, by By Device Type, 2021 - 2030 (USD Million) 11.3.4.4.3. South Korea Market, by End-User, 2021 - 2030 (USD Million) 11.3.4.5. Rest of ASIA PACIFIC 11.3.4.5.1. Rest of ASIA PACIFIC Market, by By Product, 2021 - 2030 (USD Million) 11.3.4.5.2. Rest of ASIA PACIFIC Market, by By Device Type, 2021 - 2030 (USD Million) 11.3.4.5.3. Rest of ASIA PACIFIC Market, by End-User, 2021 - 2030 (USD Million) 11.4. Latin America 11.4.1. Latin America Market, by By Product, 2021 - 2030 (USD Million) 11.4.2. Latin America Market, by By Device Type, 2021 - 2030 (USD Million) 11.4.3. Latin America Market, by End-User, 2021 - 2030 (USD Million) 11.4.4. Latin America Market, by country, 2021 - 2030 (USD Million) 11.4.4.1. Brazil 11.4.4.1.1. Brazil Market, by By Product, 2021 - 2030 (USD Million) 11.4.4.1.2. Brazil Market, by By Device Type, 2021 - 2030 (USD Million) 11.4.4.1.3. Brazil Market, by End-User, 2021 - 2030 (USD Million) 11.4.4.2. Mexico 11.4.4.2.1. Mexico Market, by By Product, 2021 - 2030 (USD Million) 11.4.4.2.2. Mexico Market, by By Device Type, 2021 - 2030 (USD Million) 11.4.4.2.3. Mexico Market, by End-User, 2021 - 2030 (USD Million) 11.4.4.3. Rest of the Latin America 11.4.4.3.1. Rest of the Latin America Market, by By Product, 2021 - 2030 (USD Million) 11.4.4.3.2. Rest of the Latin America Market, by By Device Type, 2021 - 2030 (USD Million) 11.4.4.3.3. Rest of the Latin America Market, by End-User, 2021 - 2030 (USD Million) 11.5. MEA 11.5.1. MEA Market, by By Product, 2021 - 2030 (USD Million) 11.5.2. MEA Market, by By Device Type, 2021 - 2030 (USD Million) 11.5.3. MEA Market, by End-User, 2021 - 2030 (USD Million) 11.5.4. MEA Market, by Region, 2021 - 2030 (USD Million) 12. Competitive Landscape 12.1 Becton, Dickinson, and Company 12.1.1. Company overview 12.1.2. Financial performance 12.1.3. Product Portfolio Analysis 12.1.4. Business Strategy & Recent Development 12.2. Pfizer Inc. 12.2.1. Company overview 12.2.2. Financial performance 12.2.3. Product Portfolio Analysis 12.2.4. Business Strategy & Recent Development 12.3. Teva Pharmaceuticals Industries Ltd. 12.3.1. Company overview 12.3.2. Financial performance 12.3.3. Product Portfolio Analysis 12.3.4. Business Strategy & Recent Development 12.4. Eli Lilly and Company 12.4.1. Company overview 12.4.2. Financial performance 12.4.3. Product Portfolio Analysis 12.4.4. Business Strategy & Recent Development 12.5. Baxter International, Inc. 12.5.1. Company overview 12.5.2. Financial performance 12.5.3. Product Portfolio Analysis 12.5.4. Business Strategy & Recent Development 12.6. Schott AG 12.6.1. Company overview 12.6.2. Financial performance 12.6.3. Product Portfolio Analysis 12.6.4. Business Strategy & Recent Development 12.7. Gerresheimer 12.7.1. Company overview 12.7.2. Financial performance 12.7.3. Product Portfolio Analysis 12.7.4. Business Strategy & Recent Development 12.8. Ypsomed 12.8.1. Company overview 12.8.2. Financial performance 12.8.3. Product Portfolio Analysis 12.8.4. Business Strategy & Recent Development 12.9. B. Braun Melsungen 12.9.1. Company overview 12.9.2. Financial performance 12.9.3. Product Portfolio Analysis 12.9.4. Business Strategy & Recent Development List of Tables (54 Tables) TABLE 1. Market, By Product, 2021-2030 (USD Million) TABLE 2. Market FOR Freeze Dried Products, BY REGION, 2021-2030 (USD Million) TABLE 3. Market FOR Injectable Sterile Products, BY REGION, 2021-2030 (USD Million) TABLE 4. Market, By Device Type, 2021-2030 (USD Million) TABLE 5. Market FOR Convention Injectables, BY REGION, 2021-2030 (USD Million) TABLE 6. Market FOR Auto-Injectors, BY REGION, 2021-2030 (USD Million) TABLE 7. Market FOR Pen-Injectables, BY REGION, 2021-2030 (USD Million) TABLE 8. Market FOR Pre-filled syringes, BY REGION, 2021-2030 (USD Million) TABLE 9. Market FOR Wearable, BY REGION, 2021-2030 (USD Million) TABLE 10. Market, BY END-USER, 2021-2030 (USD Million) TABLE 11. Market FOR Hospitals, BY REGION, 2021-2030 (USD Million) TABLE 12. Market FOR Home Care Settings, BY REGION, 2021-2030 (USD Million) TABLE 13. Market FOR Others, BY REGION, 2021-2030 (USD Million) TABLE 14. Market, BY Application, 2021-2030 (USD Million) TABLE 15. Market FOR Hormonal Disorders, BY REGION, 2021-2030 (USD Million) TABLE 16. Market FOR Auto-Immune Diseases, BY REGION, 2021-2030 (USD Million) TABLE 17. Market FOR Oncology, BY REGION, 2021-2030 (USD Million) TABLE 18. Market FOR Orphan/Rare Diseases, BY REGION, 2021-2030 (USD Million) TABLE 19. Market FOR Others, BY REGION, 2021-2030 (USD Million) TABLE 20. Market, BY REGION, 2021-2030 (USD Million) TABLE 21. NORTH AMERICA Market, BY COUNTRY, 2021-2030 (USD Million) TABLE 22. NORTH AMERICA Market, By Product, 2021-2030 (USD Million) TABLE 23. NORTH AMERICA Market, By Device Type, 2021-2030 (USD Million) TABLE 24. NORTH AMERICA Market, BY END-USER, 2021-2030 (USD Million) TABLE 25. EUROPE Market, BY COUNTRY, 2021-2030 (USD Million) TABLE 26. EUROPE Market, By Product, 2021-2030 (USD Million) TABLE 27. EUROPE Market, By Device Type, 2021-2030 (USD Million) TABLE 28. EUROPE Market, BY END-USER, 2021-2030 (USD Million) TABLE 29. ASIA-PACIFIC Market, BY COUNTRY, 2021-2030 (USD Million) TABLE 30. ASIA-PACIFIC Market, By Product, 2021-2030 (USD Million) TABLE 31. ASIA-PACIFIC Market, By Device Type, 2021-2030 (USD Million) TABLE 32. ASIA-PACIFIC Market, BY END-USER, 2021-2030 (USD Million) TABLE 33. LAMEA Market, BY COUNTRY, 2021-2030 (USD Million) TABLE 34. LAMEA Market, By Product, 2021-2030 (USD Million) TABLE 35. LAMEA Market, By Application, 2021-2030 (USD Million) TABLE 36. LAMEA Market, BY END-USER, 2021-2030 (USD Million) TABLE 37. Becton, Dickinson, and Company: COMPANY SNAPSHOT TABLE 38. Becton, Dickinson, and Company: OPERATING SEGMENTS TABLE 39. Pfizer Inc.: COMPANY SNAPSHOT TABLE 40. Pfizer Inc.: OPERATING SEGMENTS TABLE 41. Teva Pharmaceuticals Industries Ltd.: COMPANY SNAPSHOT TABLE 42. Teva Pharmaceuticals Industries Ltd.: OPERATING SEGMENTS TABLE 43. Eli Lilly and Company: COMPANY SNAPSHOT TABLE 44. Eli Lilly and Company: OPERATING SEGMENTS TABLE 45. Baxter International, Inc.: COMPANY SNAPSHOT TABLE 46. Baxter International, Inc.: OPERATING SEGMENTS TABLE 47. Schott AG: COMPANY SNAPSHOT TABLE 48. Schott AG: OPERATING SEGMENTS TABLE 49. Gerresheimer: COMPANY SNAPSHOT TABLE 50. Gerresheimer: OPERATING SEGMENTS TABLE 51. Ypsomed: COMPANY SNAPSHOT TABLE 52. Ypsomed: OPERATING SEGMENTS TABLE 53. B. Braun Melsungen: COMPANY SNAPSHOT TABLE 54. B. Braun Melsungen: OPERATING SEGMENTS List of Figures (24 Figures) Figure 1 Market: Research Methodology Steps Figure 2 Research Design Figure 3 Breakdown of Primaries: Market Figure 4 Research Methodology: Hypothesis Building Figure 5 Market: Product-Based Estimation Figure 6 Top 9 Companies with Highest No. Of Patent in Last 9 Years Figure 7 No. Of Patents Granted Per Year, 2019–2020 Figure 8 Import Data for Injectable Drug Delivery, By Country, 2016–2020 (USD Thousand) Figure 9 Export Data for Injectable Drug Delivery, By Country, 2016–2020 (USD Thousand) Figure 10 Data Triangulation Methodology Figure 11 Market, By Device Type, 2019 vs. 2025 (USD Million) Figure 12 Market Share, By End-User, 2019 vs. 2025 (USD Million) Figure 13 Market Share, By Product, 2019 vs. 2025 (USD Million) Figure 14 Market Share, By Application, 2019 vs. 2025 (USD Million) Figure 15 Geographical Snapshot of the Market Figure 16 Injectable Sterile Products to Witness Higher CAGR in Market for Product Segment during Forecast Period. Figure 17 Hospitals to Witness Higher CAGR in Market for End-User Segment during Forecast Period. Figure 18 Convention Injectables to Witness Higher CAGR in Market for Device Type Segment during Forecast Period. Figure 19 Hormonal Disorders to Witness Higher CAGR in Market for Application Segment during Forecast Period. Figure 20 North America Accounted for the Largest Share of the Market, By Regional Basis, in 2019 Figure 21 Market: Drivers, Restraints, Opportunities, and Challenges Figure 22 North America: Market Snapshot Figure 23 Asia Pacific: Market Snapshot Figure 24 Vendor Dive: Evaluation Overview